GOLDMAN SACHS GROUP INC - AN2 THERAPEUTICS INC ownership

AN2 THERAPEUTICS INC's ticker is and the CUSIP is 037326105. A total of 38 filers reported holding AN2 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of AN2 THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$332,410
+13.1%
39,107
+100.6%
0.00%
Q1 2022$294,00019,4970.00%
Other shareholders
AN2 THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
TCG Crossover Management, LLC 2,678,209$43,065,6006.34%
Octagon Capital Advisors LP 867,575$13,950,6062.14%
RA Capital Management 5,551,295$89,264,8241.76%
Frazier Life Sciences Management, L.P. 1,388,889$22,333,3351.48%
Avidity Partners Management LP 1,089,400$17,517,5520.70%
BVF INC/IL 1,563,963$25,148,5250.68%
Monashee Investment Management LLC 99,495$1,599,8800.67%
Nantahala Capital Management 356,789$5,737,1670.49%
ACUTA CAPITAL PARTNERS, LLC 13,300$213,8640.14%
ADAGE CAPITAL PARTNERS GP, L.L.C. 905,556$14,561,3400.03%
View complete list of AN2 THERAPEUTICS INC shareholders